Searched for
CIPLA RESPIRATORY HEALTH
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Cipla Foundation, Tata IISc launch centre for advanced pulmonary care & researchCipla Foundation and IISc are joining forces to create a new Centre for Pulmonary Medicine in Bengaluru. This facility will offer advanced ...
- Cipla Q3 Results: Net profit plunges 57% YoY to Rs 676 croreCipla Q3 Results: Cipla reported a 57% YoY drop in net profit to Rs 676 crore, impacted by lower gRevlimid sales in North America. Despite ...
- Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug YurpeakIn an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...
- Cipla rolls out mobile application for asthma screeningCipla has launched a mobile app, CipAir, to facilitate early screening for asthma in India. The app addresses the significant asthma burden...
- Cipla Q2 hit by seasonal chill, but investors need not worryCipla's September-quarter performance saw a 5.6% increase in consolidated net sales and a 15% rise in net profit despite slow seasonal grow...
- Cipla reports Rs 1049 crore net profit in Q3FY24, on strong US, India salesDrug maker Cipla reported a 33% year-on-year (YoY) jump in net profit to Rs 1049 crore in Q3FY24, led by strong US and India sales momentum.
- Cipla Q2 Results: Net profit jumps 45% YoY to Rs 1131 croreCipla's India business that contributes 42% to overall revenue grew 10% YoY to Rs 2817 crore in Q2FY24 with continued momentum across brand...
- US unit of India's Cipla recalls six batches of bronchospasm inhalerIndian pharmaceutical company Cipla has recalled six batches of its Albuterol Sulfate HFA Inhalation Aerosol in the US due to a container d...
- Cipla expects sales of branded generics to cross $1 billion this fiscalCipla's branded generics business reported sales of around ₹6,000 crore in FY21. The drug maker's India business, which consists of prescri...
- Cipla submits application with USFDA for generic version of asthma drugDrug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, ...
- Cipla hits 15% upper circuit as USFDA gives final approval to Albuterol Inhalation AerosolFollowing the development, the scrip hit its 15 per cent upper circuit limit at Rs 589.95.
- Cipla gets final approval from USFDA for Albuterol Sulfate Inhalation AerosolIn a regulatory filing the company said "it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfa...
- Cipla eyes filing over 20 ANDAs in US this fiscalThe company said it will continue to focus on investing towards building its speciality franchise through a combination of development with...
- Cipla-Novartis patent row: DIPP looking into merit of caseNovartis merely imports a negligible quantity of these products manufactured in Switzerland as per its own data filed before the Patent off...
Load More
